A Form 4 filed on September 22, 2026 reports that Ralph Alvarez, a director of Eli Lilly & Co (NYSE:LLY), acquired 10.6591 shares of common stock on September 21, 2026 through the company's Directors' Deferral Plan in lieu of cash compensation.

Key Highlights

  • Reporting person: Ralph Alvarez, identified as a Director of Eli Lilly & Co
  • Transaction date: September 21, 2026, with 10.6591 shares acquired at a price of $1,164.89 per share
  • Deferral plan: The acquired shares were deferred as stock units under the Lilly Directors' Deferral Plan and will be settled in common stock following the reporting person's separation from service
  • Direct holdings following transaction: 55,838.2192 shares of common stock held directly
  • Indirect holdings: 758 shares of common stock held indirectly by trust, with Alvarez disclaiming beneficial ownership except to the extent of his pecuniary interest
  • Filing signed by: Christopher Anderson for Ralph Alvarez, pursuant to authorization on file

Ralph Alvarez Defers Director Compensation as Eli Lilly Stock Units

According to the filing, Ralph Alvarez, a director at Eli Lilly & Co (NYSE:LLY), acquired 10.6591 shares of Eli Lilly common stock on September 21, 2026, at a price of $1,164.89 per share. The transaction is coded as an acquisition (A) in Table I of the Form 4, reflecting non-derivative securities acquired.

The filing discloses that, at the election of the reporting person, the acquired shares were deferred in lieu of cash compensation as stock units under the Lilly Directors' Deferral Plan. Per the filing, these units "will be settled in shares of common stock following the reporting person's separation from service." Following this transaction, Alvarez directly holds 55,838.2192 shares of Eli Lilly common stock.

The filing also notes that Alvarez indirectly holds 758 shares through a trust. The filing states that "the Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein." No derivative securities transactions were reported. The Form 4 was filed by One Reporting Person and was signed by Christopher Anderson on behalf of Ralph Alvarez on September 22, 2026, pursuant to authorization on file.

What Was Disclosed

The filing reports a single acquisition of 10.6591 shares of Eli Lilly common stock by director Ralph Alvarez on September 21, 2026, deferred as stock units under the Lilly Directors' Deferral Plan in lieu of cash compensation, bringing his direct holdings to 55,838.2192 shares.